DELIVRA HEALTH BRANDS INC (DHB.CA) Fundamental Analysis & Valuation

TSX-V:DHB • CA24703H2019

0.17 CAD
+0.01 (+6.25%)
Last: Mar 4, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This DHB.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

DHB gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 34 industry peers in the Pharmaceuticals industry. The financial health of DHB is average, but there are quite some concerns on its profitability. DHB is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. DHB.CA Profitability Analysis

1.1 Basic Checks

  • In the past year DHB has reported negative net income.
  • DHB had a negative operating cash flow in the past year.
  • In the past 5 years DHB reported 4 times negative net income.
  • DHB had negative operating cash flow in 4 of the past 5 years.
DHB.CA Yearly Net Income VS EBIT VS OCF VS FCFDHB.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M

1.2 Ratios

  • The Return On Assets of DHB (-8.86%) is comparable to the rest of the industry.
  • With a Return On Equity value of -18.62%, DHB perfoms like the industry average, outperforming 52.94% of the companies in the same industry.
Industry RankSector Rank
ROA -8.86%
ROE -18.62%
ROIC N/A
ROA(3y)-1.81%
ROA(5y)-43.05%
ROE(3y)-5.55%
ROE(5y)-101.64%
ROIC(3y)N/A
ROIC(5y)N/A
DHB.CA Yearly ROA, ROE, ROICDHB.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200

1.3 Margins

  • Looking at the Gross Margin, with a value of 49.16%, DHB is in the better half of the industry, outperforming 67.65% of the companies in the same industry.
  • DHB's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for DHB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 49.16%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.54%
GM growth 5Y20.78%
DHB.CA Yearly Profit, Operating, Gross MarginsDHB.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. DHB.CA Health Analysis

2.1 Basic Checks

  • DHB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for DHB remains at a similar level compared to 1 year ago.
  • DHB has more shares outstanding than it did 5 years ago.
  • DHB has a worse debt/assets ratio than last year.
DHB.CA Yearly Shares OutstandingDHB.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
DHB.CA Yearly Total Debt VS Total AssetsDHB.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -19.45, we must say that DHB is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -19.45, DHB is doing worse than 88.24% of the companies in the same industry.
  • A Debt/Equity ratio of 0.43 indicates that DHB is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.43, DHB is in line with its industry, outperforming 44.12% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.43
Debt/FCF N/A
Altman-Z -19.45
ROIC/WACCN/A
WACC7.17%
DHB.CA Yearly LT Debt VS Equity VS FCFDHB.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M 80M 100M

2.3 Liquidity

  • A Current Ratio of 3.14 indicates that DHB has no problem at all paying its short term obligations.
  • DHB has a Current ratio of 3.14. This is amongst the best in the industry. DHB outperforms 82.35% of its industry peers.
  • DHB has a Quick Ratio of 2.35. This indicates that DHB is financially healthy and has no problem in meeting its short term obligations.
  • DHB has a better Quick ratio (2.35) than 88.24% of its industry peers.
Industry RankSector Rank
Current Ratio 3.14
Quick Ratio 2.35
DHB.CA Yearly Current Assets VS Current LiabilitesDHB.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. DHB.CA Growth Analysis

3.1 Past

  • The earnings per share for DHB have decreased strongly by -560.71% in the last year.
  • The Revenue has grown by 13.01% in the past year. This is quite good.
  • Measured over the past years, DHB shows a quite strong growth in Revenue. The Revenue has been growing by 11.44% on average per year.
EPS 1Y (TTM)-560.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.76%
Revenue 1Y (TTM)13.01%
Revenue growth 3Y17.99%
Revenue growth 5Y11.44%
Sales Q2Q%1.39%

3.2 Future

  • DHB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 49.00% yearly.
  • Based on estimates for the next years, DHB will show a quite strong growth in Revenue. The Revenue will grow by 13.79% on average per year.
EPS Next Y80%
EPS Next 2Y49%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year13.99%
Revenue Next 2Y13.79%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
DHB.CA Yearly Revenue VS EstimatesDHB.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5M 10M 15M
DHB.CA Yearly EPS VS EstimatesDHB.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2025 2026 2027 0 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

4

4. DHB.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • DHB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • DHB is valuated correctly with a Price/Forward Earnings ratio of 15.00.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of DHB indicates a somewhat cheap valuation: DHB is cheaper than 73.53% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 24.82. DHB is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 15
DHB.CA Price Earnings VS Forward Price EarningsDHB.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

  • 61.76% of the companies in the same industry are more expensive than DHB, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 10.04
DHB.CA Per share dataDHB.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2 0.3 0.4

4.3 Compensation for Growth

  • DHB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as DHB's earnings are expected to grow with 49.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DHB.CA Dividend Analysis

5.1 Amount

  • No dividends for DHB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DHB.CA Fundamentals: All Metrics, Ratios and Statistics

DELIVRA HEALTH BRANDS INC

TSX-V:DHB (3/4/2026, 7:00:00 PM)

0.17

+0.01 (+6.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-25
Earnings (Next)05-19
Inst Owners1.86%
Inst Owner ChangeN/A
Ins Owners13.18%
Ins Owner ChangeN/A
Market Cap5.31M
Revenue(TTM)13.41M
Net Income(TTM)-806.00K
Analysts84.44
Price Target0.73 (329.41%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 15
P/S 0.4
P/FCF N/A
P/OCF N/A
P/B 1.23
P/tB 1.23
EV/EBITDA 10.04
EPS(TTM)-0.03
EYN/A
EPS(NY)0.01
Fwd EY6.66%
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.43
BVpS0.14
TBVpS0.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -8.86%
ROE -18.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 49.16%
FCFM N/A
ROA(3y)-1.81%
ROA(5y)-43.05%
ROE(3y)-5.55%
ROE(5y)-101.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.54%
GM growth 5Y20.78%
F-Score3
Asset Turnover1.48
Health
Industry RankSector Rank
Debt/Equity 0.43
Debt/FCF N/A
Debt/EBITDA 4.42
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.14
Quick Ratio 2.35
Altman-Z -19.45
F-Score3
WACC7.17%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-560.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.76%
EPS Next Y80%
EPS Next 2Y49%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)13.01%
Revenue growth 3Y17.99%
Revenue growth 5Y11.44%
Sales Q2Q%1.39%
Revenue Next Year13.99%
Revenue Next 2Y13.79%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y54.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year212.7%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y38.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.19%
OCF growth 3YN/A
OCF growth 5YN/A

DELIVRA HEALTH BRANDS INC / DHB.CA FAQ

Can you provide the ChartMill fundamental rating for DELIVRA HEALTH BRANDS INC?

ChartMill assigns a fundamental rating of 3 / 10 to DHB.CA.


What is the valuation status for DHB stock?

ChartMill assigns a valuation rating of 4 / 10 to DELIVRA HEALTH BRANDS INC (DHB.CA). This can be considered as Fairly Valued.


What is the profitability of DHB stock?

DELIVRA HEALTH BRANDS INC (DHB.CA) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for DHB stock?

The Earnings per Share (EPS) of DELIVRA HEALTH BRANDS INC (DHB.CA) is expected to grow by 80% in the next year.